Retatrutide

Moderate Evidence

TL;DR

• Retatrutide is investigational and is not an FDA-approved medicine.
• It is designed as a triple agonist at GIP, GLP-1, and glucagon receptors.
• Phase 2 obesity data were strong enough to make it one of the highest-interest metabolic peptides in the pipeline.
• Any non-trial “retatrutide” product should be treated as high risk because there is no approved commercial supply pathway.

What It Is

Retatrutide is an investigational peptide-based incretin therapy being developed by Eli Lilly. Unlike semaglutide, which targets GLP-1 receptors, and tirzepatide, which targets GIP and GLP-1 receptors, retatrutide is designed to activate GIP, GLP-1, and glucagon receptors.

That triple-agonist design is why the drug is closely watched in obesity, metabolic disease, and liver-disease research. It is also why PeptideUnicorn separates retatrutide from approved prescription medicines: the evidence is promising, but the product remains investigational.

Evidence Summary

Study	Year	N	Outcome	Limitations
Phase 2 obesity trial	2023	338	Retatrutide produced dose-dependent weight reduction at 24 and 48 weeks in adults with obesity.	Phase 2 trial; not an approval study; sponsor-funded.
TRIUMPH phase 3 program	Ongoing	Varies	ClinicalTrials.gov lists phase 3 studies evaluating retatrutide in obesity and related metabolic conditions.	Results and regulatory review are pending unless announced by the sponsor or regulators.

Evidence level: Moderate because the obesity data include human randomized trial evidence, but retatrutide remains investigational.

Legal Status by Jurisdiction

US (FDA). Retatrutide is investigational and is not FDA-approved. It should not be treated as equivalent to prescription semaglutide or tirzepatide.

UK (MHRA). Retatrutide is not licensed as a prescription medicine. Legitimate access is expected to be through clinical trials unless and until authorization changes.

AU (TGA). Retatrutide should be treated as investigational. Any therapeutic claims outside authorized trial settings require careful scrutiny.

WADA. Athletes should verify current anti-doping rules before participating in any metabolic-drug trial or exposure scenario.

Typical Use Protocols

There is no approved clinical-use protocol for retatrutide. Public dose information comes from trials and should not be converted into self-administration guidance.

Side Effects and Contraindications

Published retatrutide studies describe gastrointestinal adverse events as common, broadly consistent with incretin-based therapy. Because retatrutide is investigational, the long-term safety profile, contraindications, and monitoring requirements are still being characterized.

How to Source It

The regulated path for retatrutide is clinical-trial participation. PeptideUnicorn does not recommend research-vendor or gray-market retatrutide products for personal use.

Change Log

• 2026-05-27: Initial PeptideUnicorn profile published.

References

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389:514-526.
2. ClinicalTrials.gov. TRIUMPH-1 study of retatrutide in participants with obesity or overweight.
3. Eli Lilly and Company. Retatrutide phase 3 program and obesity pipeline updates.

Continue Reading

Readers also explore

All peptides →

Metabolic

Tirzepatide

Dual GIP and GLP-1 Receptor Agonist

Type 2 diabetes · Chronic weight management · Obstructive sleep apnea in adults with obesity

Open profile

Metabolic

Semaglutide

GLP-1 Receptor Agonist

Type 2 diabetes · Chronic weight management · Cardiovascular risk reduction in selected patients

Open profile